Wall Street Thinks This Beaten-Down Growth Stock Can Soar 85% in 2025. Should You Buy It Now?

Moderna (MRNA) has been a classic example of how one successful product can propel a biotech stock to new heights in a matter of months. 

Before developing its COVID-19 vaccine, Moderna had no approved products. However, its success with the vaccine led to a staggering 443.2% stock surge in 2020. Despite growing interest in mRNA therapies, Moderna’s stock has been on a downward trajectory since then.